Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 4/20 | 0.39 |
| ▸ | F10 | P00742 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | APOB | P04114 | 1/20 | 0.34 |
| ▸ | MTTP | P55157 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793528 | 0.90 | NR3C1 (0.41) | NR3C1ALDH1A1GAAMAPTROCK2 | |
| SCHEMBL6492299 | 0.86 | APOB (0.39) | NR3C1GCGRHTTNPSR1APOB | |
| SCHEMBL6499352 | 0.85 | MAPT (0.39) | GCGRF10MAPTANO1 | |
| SCHEMBL6491092 | 0.84 | CYP3A4 (0.38) | NR3C1GCGRALDH1A1MAPTROCK2 | |
| SCHEMBL6788065 | 0.81 | SMO (0.42) | GAAAPOBMTTP | |
| SCHEMBL6498587 | 0.81 | APOB (0.44) | NR3C1GCGRHTTNPSR1APOB | |
| SCHEMBL6500278 | 0.80 | NR3C1 (0.46) | NR3C1GCGRF10MAPTANO1 | |
| SCHEMBL6491615 | 0.80 | SREBF2 (0.39) | ALDH1A1MAPTNPSR1APOBMTTP | |
| SCHEMBL6489597 | 0.80 | MAPT (0.40) | GCGRF10MAPTANO1 | |
| SCHEMBL6490015 | 0.80 | GCGR (0.41) | GCGRF10ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | NR3C1 1457/4885GCGR 1784/4885F10 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.